Hackett Geoffrey, Kirby Michael, Edwards David, Jones T Hugh, Rees Jonathan, Muneer Asif
Good Hope Hospital, Birmingham, UK.
University of Bedfordshire, Luton, UK.
Int J Clin Pract. 2017 Mar;71(3-4). doi: 10.1111/ijcp.12901. Epub 2017 Mar 20.
To address widespread media and scientific concerns over the appropriate treatment of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British Society for Sexual Medicine developed eight consensus statements, based on current scientific evidence to address these controversial issues. These statements were in no-way designed to replace the published evidence-based guidelines on the subject developed by various professional organisations, but to provide specific answers to several current controversial issues. This review examined evidence from Medline, EMBASE and Cochrane searches on HG, T Therapy and cardiovascular safety from May 2005 to May 2015, which revealed 1714 articles, with 52 clinical trials and 32 placebo-controlled randomised controlled trials. The task force developed the following eight key statements.
为应对媒体和科学界对睾酮疗法（T疗法）治疗迟发性性腺功能减退（TDS）的适当性的广泛关注，英国性医学学会执行委员会根据当前科学证据制定了八项共识声明，以解决这些有争议的问题。这些声明绝非旨在取代各专业组织制定的关于该主题的已发表的循证指南，而是为当前几个有争议的问题提供具体答案。本综述检索了2005年5月至2015年5月期间Medline、EMBASE和Cochrane数据库中关于迟发性性腺功能减退、睾酮疗法和心血管安全性的证据，共检索到1714篇文章，其中有52项临床试验和32项安慰剂对照随机对照试验。特别工作组制定了以下八项关键声明。
